PPT-Withdrawal of pharmacological therapy for heart failure in recovered dilated cardiomyopathy

Author : taylor | Published Date : 2022-06-01

TREDHF Brian P Halliday MBChB PhD On behalf of Sanjay K Prasad PI John GF Cleland coPI Rebecca Wassall Amrit Lota Zohya Khalique John Gregson Dudley J Pennell

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Withdrawal of pharmacological therapy fo..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Withdrawal of pharmacological therapy for heart failure in recovered dilated cardiomyopathy: Transcript


TREDHF Brian P Halliday MBChB PhD On behalf of Sanjay K Prasad PI John GF Cleland coPI Rebecca Wassall Amrit Lota Zohya Khalique John Gregson Dudley J Pennell Stuart D Rosen Martin R Cowie and the TREDHF investigators . A diagram and echocardiogram comparing a normal heart and a heart with DCM are shown in 57375gure 1a and 57375gure 1b This condition is the most common form of cardiomyopathy and accounts for approximately 5560 of all childhood cardiomyopathies Acco Dilated cardiomyopathy is a disease characteriz ed by enlargement of all four heart cham bers The walls of the ventricles are abnormally thin and the heart has a severely reduced ability to contract Cats with dilated cardiomyopathy usually have cong heartache peripartum . cardiomyopathy . د. حسين محمد جمعة . اختصاصي الامراض الباطنة . البورد العربي . كلية طب الموصل . 2010. Laura Wexler MD, FAHA, FACC. Adj. Professor of Medicine/Cardiology. University of Cincinnati College of Medicine. Department of Veterans Affairs Medical Center. Goals of therapy. Treatment of acute exacerbation – Diuretics are the main stay of therapy. Blake Wachter, Spring 2009. 蛸壺. Case Presentation. 57 year old women presenting to the ED with complaint of 2 hours of crushing pressure-like chest pain, non radiating. She says she feels short of breath and diaphoretic but denies nausea and vomiting. She does not have a family or personal history of heart disease. She denies a life long history of smoking. Her past medical history is significant for obesity, DM II, OA. She takes . Department of internal medicine 1. with course of cardio-vascular pathology. disease of the heart muscle in which the heart loses its ability to. pump blood effectively. the heart muscle becomes . Nonischemic. /Familial dilated cardiomyopathy. Myocardial ischemia. Valvular disease. Peripartum. cardiomyopathy. Toxin. Non-dilated. Myocarditis. Myocardial ischemia. Valvular disease. Infiltrative cardiomyopathy. in the Molecular Motors. that . Power . the Heart. Myosin Molecular . Motor. David M. Warshaw, Ph.D.. Molecular Physiology & Biophysics. Hank Gathers. Reggie Lewis. Genetic Defects in Myosin Motor. Zelda Summers & K M Gangineni. Introduction. GHB is a naturally occurring short chain fatty acid related to gamma amino butyric acid found in peripheral organs including heart, liver, brain, kidney, cardiac and skeletal muscles.. Page 1 Rev 2 .0 Patient Information Non - Ischemic Cardiomyopathy 395 respiratory or cardiac failure. Among them, cardiovascular involvement is a leading cause of morbidity and mortality. There are relatively few cases reporting cardiac pISSN 2384-1095eISSN 2384-11 1 Familial dilated cardiomyopathy Description Familial dilated cardiomyopathy is a genetic form of heart disease. It occurs when heart ( cardiac) muscle becomes thin and weakened in at least one chamb almutairi. . Assistant professor internal . medicin. dept. . (MBBS)(SBMD). CONTENET. Introduction. Epidemiology. Pathophysiology. syst. olic/. diast. olic. Risk factors. Signs and symptoms. Classification of HF severity. , MD, MHA. Consultant Heart Failure & Transplantation. Heart failure is an enormous medical and societal burden . More than 2% of the U.S. population, or almost 5 million people, are affected,. It consumes approximately 2% of the National Health Service budget in the United Kingdom, and in the United States, .

Download Document

Here is the link to download the presentation.
"Withdrawal of pharmacological therapy for heart failure in recovered dilated cardiomyopathy"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.

Related Documents